Amgen Inc. (NASDAQ:AMGN) Shares Bought by Skba Capital Management LLC

Skba Capital Management LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 17.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,160 shares of the medical research company’s stock after acquiring an additional 3,600 shares during the quarter. Skba Capital Management LLC’s holdings in Amgen were worth $6,297,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the business. CIBC Private Wealth Group LLC increased its stake in Amgen by 3.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 328,563 shares of the medical research company’s stock valued at $86,810,000 after purchasing an additional 10,946 shares during the last quarter. Joseph Group Capital Management boosted its holdings in shares of Amgen by 15.1% in the 4th quarter. Joseph Group Capital Management now owns 9,934 shares of the medical research company’s stock valued at $2,589,000 after buying an additional 1,301 shares in the last quarter. Portland Global Advisors LLC grew its position in shares of Amgen by 0.9% in the 4th quarter. Portland Global Advisors LLC now owns 23,755 shares of the medical research company’s stock valued at $6,192,000 after buying an additional 205 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Amgen during the 4th quarter worth $8,798,000. Finally, Allianz SE purchased a new stake in Amgen in the fourth quarter valued at $9,933,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Truist Financial dropped their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Piper Sandler Companies restated an “overweight” rating and set a $310.00 price target on shares of Amgen in a research note on Thursday, January 2nd. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Wells Fargo & Company reissued an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $314.04.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Trading Up 0.4 %

Shares of AMGN stock opened at $306.95 on Monday. The firm’s 50-day simple moving average is $301.08 and its 200-day simple moving average is $297.94. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The firm has a market cap of $164.90 billion, a P/E ratio of 40.66, a PEG ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is currently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.